Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence.

Department of Veterans Affairs, VISN 3 Mental Illness, Research, Education and Clinical Center, Lyons, New Jersey, USA.
Canadian journal of psychiatry. Revue canadienne de psychiatrie (Impact Factor: 2.48). 10/2002; 47(7):671-5.
Source: PubMed

ABSTRACT To examine the efficacy of atypical neuroleptics for decreasing craving and drug relapses during protracted withdrawal in individuals dually diagnosed with schizophrenia and cocaine dependence.
We conducted a 6-week, open-label pilot study comparing risperidone with typical neuroleptics in a sample of withdrawn cocaine-dependent schizophrenia patients.
Preliminary results suggest that individuals treated with risperidone had significantly less cue-elicited craving and substance abuse relapses at study completion. Further, they showed a trend toward a greater reduction in negative and global symptoms of schizophrenia.
Atypical neuroleptics may help reduce craving and relapses in this population. Future research should include more rigorous double-blind placebo-controlled studies with this class of medications.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Substance Use Disorders (SUDs) are common among patients with schizophrenia and dramatically worsen their outcome. In the last years, the use of Atypical Antipsychotics (AAPs) in dual diagnosis has become an encouraging clinical strategy. Aim of the present paper is to provide a systematic literature review on efficacy and safety of AAPs use in schizophrenic patients with comorbid SUD. Methods: We searched PubMed to identify original studies pertaining the use of AAPs in treating dual-diagnosed schizophrenic patients. Results: We found 12 papers that met our inclusion/exclusion criteria: five randomized clinical trials, two open label trials and five observational studies. 1432 schizophrenic patients, 905 of them with a comorbid SUD, were involved. Olanzapine, Risperidone and Clozapine were the most prescribed AAPs; alcohol, cannabis and cocaine the most frequent substances of abuse. None of the selected studies was placebo-controlled: AAPs were compared to Typical Antipsychotics (TAPs) or one another. AAPs resulted usually, but not always, more efficacious than TAPs on substance related problems. In those studies comparing different AAPs, clozapine showed better results than other treatments, whereas no significant differences emerged between risperidone and olanzapine. In terms of safety, AAPs were usually well tolerated. Conclusions: Our review suggests that AAPs, in particular clozapine, olanzapine and risperidone, may be a promising therapeutic option for schizophrenic patients with comorbid SUD. On the other hand, given the limited number of randomized controlled trials and the lack of placebo arms, further studies are needed to better address this point.
    Journal of Schizophrenia Research. 08/2014; 1(1):1-12.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Summary The consumption of cocaine among people included in Methadone Maintenance Therapy (MMT) is a widely identifi ed phenom- enon, but clinical experience and the literature have highlighted the diffi culty of fi nding an effective pharmacological alternative for cocaine abusers. The aim of this study was to assess the use of olanzapine as a therapy for reducing the use of cocaine in MMT while implementing a more controlled design. A randomized clinical trial has been applied to 60 subjects assigned to three MMT programmes. The independent variable was treatment with olanzapine at three dose levels (0, 5 and 10 mg/day), with three treatment groups being formed; they comprised 20, 21 and 19 subjects, respectively. The outcome variable was the percentage of positive urine tests for cocaine consumption, as estimated by means of urine monitoring using immunoassay, during the fi rst three months after the start of treatment. For the data analysis, MANOVA and the hierarchical regression model were used. The mean proportion of previous cocaine consumption was 25.8% (S.D.= 26.4; range 0-100), with no differences between the treat- ment groups (F(2,57) = 0.167; p= 0.845). Hierarchical regression analysis showed a signifi cant model in fi nal step (F(5,54)= 8.61; p ≤ 0.001), with an explained variance of 44.3% (R (2,57) 0.001), with an explained variance of 44.3% (R (2,57) 2 = 0.443). The semi-partial correlation coeffi cients (rs-m) indicated signifi cant
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate and compare the effectiveness of available treatments for cocaine dependence in schizophrenic patients. We searched articles published between May 2002 and June 2012 in the following databases: Scopus, Pubmed and Web of Knowledge. The key words utilised were "schizophrenia", "dementia praecox", "schizophrenic disorder", "cocaine related disorder", "cocaine abuse", "cocaine addiction", "cocaine dependence", "treatment", "therapeutic", and "drug therapy". Original articles in English, Portuguese and Spanish were selected. Controlled, double-blind and open-label studies involving only human subjects were included in this review. We found studies on typical and atypical antipsychotics and one monoamine transporter antagonist. There were few indications of the effectiveness of atypical antipsychotic medications for the treatment of cocaine dependence in patients with schizophrenia. We suggest that further studies be conducted with atypical antipsychotic medicationsand greater methodological strictness, including using a placebo group in the studies, so that health professionals can determine the real effectiveness of this class of medication for the treatment of cocaine dependence in schizophrenic patients.
    Current Neuropharmacology 09/2013; 11(5):484-490. · 2.03 Impact Factor


Available from